|Generic Name||Tadalafil 20 mg|
Mandrive for ED+BPH (erectile dysfunction + symptoms of benign prostatic hyperplasia)
Pharmacology : Inhibition of phosphodiesterase type 5 (PDE5) by tadalafil increases the concentrations of cyclic guanosine monophosphate (cGMP), resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed.
Mandrive-20 : Enhances the effect of nitric oxide at the nerve ending and endothelial cells in the corpus cavernosum by inhibiting PDE5 in the corpus cavernosum of the penis. This results in vasodilation, increased inflow of blood into the corporus cavernosum, and ensuing penile erection upon sexual stimulation.FDA Drug Approvals 2013
Distribution : Tadalafil is 94% protein bound
Metabolism : Predominantly metabolized by CYP3A4 to a catechol metabolite, which undergoes further metabolism to the major circulating metabolite, methylcatechol glucuronide.
Elimination : The terminal half-life is 15 h to 17.5 h. Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61%) and to a lesser degree in the urine (approximately 36%).
Special Populations :
Unlabeled Uses : Raynaud phenomenon.
Contraindications : Administration with organic nitrates (regularly and/or intermittently); serious hypersensitivity to tadalafil.
Dosage and Administration :
Pulmonary Arterial Hypertension :
Erectile Dysfunction :
Once-daily use : PO Start with 2.5 mg once daily, taken at approximately the same time each day, without regard to timing of sexual activity. The dosage may be increased to 5 mg daily based on individual efficacy and tolerability.